For generations, cancer researchers have watched a master regulator called MYC orchestrate malignancy in the majority of human cancers while remaining stubbornly beyond the reach of medicine. Scientists at MD Anderson Cancer Center have now discovered that MYC does not act alone — it sustains itself through a molecular partnership with a protein called GSPT1 — and have built an experimental compound, GT19630, that dismantles this relationship by turning the cell's own recycling machinery against both proteins at once. The finding, published in Blood, reframes a decades-old defeat as a solvable